These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 39134023)
1. Lactoferrin/CD133 antibody conjugated nanostructured lipid carriers for dual targeting of blood-brain-barrier and glioblastoma stem cells. Zhao C; Zhu X; Yang H; Tan J; Gong R; Mei C; Cai X; Su Z; Kong F Biomed Mater; 2024 Aug; 19(5):. PubMed ID: 39134023 [TBL] [Abstract][Full Text] [Related]
2. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells. Kim JS; Shin DH; Kim JS J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480 [TBL] [Abstract][Full Text] [Related]
3. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. Song S; Mao G; Du J; Zhu X Drug Deliv; 2016 May; 23(4):1404-8. PubMed ID: 26203687 [TBL] [Abstract][Full Text] [Related]
4. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. Wu M; Fan Y; Lv S; Xiao B; Ye M; Zhu X Drug Deliv; 2016 Oct; 23(8):2720-2725. PubMed ID: 26203691 [TBL] [Abstract][Full Text] [Related]
5. Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells. Smiley SB; Yun Y; Ayyagari P; Shannon HE; Pollok KE; Vannier MW; Das SK; Veronesi MC Pharm Res; 2021 Jun; 38(6):1067-1079. PubMed ID: 34100216 [TBL] [Abstract][Full Text] [Related]
6. Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy. Zhang J; Xiao X; Zhu J; Gao Z; Lai X; Zhu X; Mao G Int J Nanomedicine; 2018; 13():3039-3051. PubMed ID: 29861635 [TBL] [Abstract][Full Text] [Related]
7. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy? Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462 [TBL] [Abstract][Full Text] [Related]
8. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Noh H; Zhao Q; Yan J; Kong LY; Gabrusiewicz K; Hong S; Xia X; Heimberger AB; Li S Cancer Lett; 2018 Oct; 433():176-185. PubMed ID: 29991446 [TBL] [Abstract][Full Text] [Related]
9. Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma. Hsu TI; Chen YP; Zhang RL; Chen ZA; Wu CH; Chang WC; Mou CY; Chan HW; Wu SH ACS Appl Mater Interfaces; 2024 May; 16(17):21722-21735. PubMed ID: 38629735 [TBL] [Abstract][Full Text] [Related]
10. Glioblastoma stem cells deliver ABCB4 transcribed by ATF3 via exosomes conferring glioblastoma resistance to temozolomide. Xu X; Zheng Y; Luo L; You Z; Chen H; Wang J; Zhang F; Liu Y; Ke Y Cell Death Dis; 2024 May; 15(5):318. PubMed ID: 38710703 [TBL] [Abstract][Full Text] [Related]
12. The Development and Applications of a Dual Optical Imaging System for Studying Glioma Stem Cells. Tai PA; Liu YL; Wen YT; Lin CM; Huynh TT; Hsiao M; Wu ATH; Wei L Mol Imaging; 2019; 18():1536012119870899. PubMed ID: 31478435 [TBL] [Abstract][Full Text] [Related]
13. Nanostructured lipid carriers based temozolomide and gene co-encapsulated nanomedicine for gliomatosis cerebri combination therapy. Chen Z; Lai X; Song S; Zhu X; Zhu J Drug Deliv; 2016 May; 23(4):1369-73. PubMed ID: 26017099 [TBL] [Abstract][Full Text] [Related]
15. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456 [TBL] [Abstract][Full Text] [Related]
16. Sequential delivery of dual drugs with nanostructured lipid carriers for improving synergistic tumor treatment effect. Xu M; Li G; Zhang H; Chen X; Li Y; Yao Q; Xie M Drug Deliv; 2020 Dec; 27(1):983-995. PubMed ID: 32611218 [TBL] [Abstract][Full Text] [Related]
17. Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review. Liao W; Fan S; Zheng Y; Liao S; Xiong Y; Li Y; Liu J Curr Med Chem; 2019; 26(31):5862-5874. PubMed ID: 29768997 [TBL] [Abstract][Full Text] [Related]
18. Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells. Chang CH; Liu WT; Hung HC; Gean CY; Tsai HM; Su CL; Gean PW BMC Cancer; 2017 Dec; 17(1):905. PubMed ID: 29284440 [TBL] [Abstract][Full Text] [Related]
19. Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers. Farshbaf M; Mojarad-Jabali S; Hemmati S; Khosroushahi AY; Motasadizadeh H; Zarebkohan A; Valizadeh H J Control Release; 2022 May; 345():371-384. PubMed ID: 35301054 [TBL] [Abstract][Full Text] [Related]
20. Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma. Kitabayashi T; Dong Y; Furuta T; Sabit H; Jiapaer S; Zhang J; Zhang G; Hayashi Y; Kobayashi M; Domoto T; Minamoto T; Hirao A; Nakada M Sci Rep; 2019 Jul; 9(1):10049. PubMed ID: 31296906 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]